Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.46 |
| ▸ | FNTB | P49356 | 16/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 16/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856398 | 0.78 | CYP11B1 (0.53) | ALDH1A1NFATC1GSK3BDYRK1A | |
| SCHEMBL4857588 | 0.77 | CYP19A1 (0.50) | ALDH1A1NFATC1GSK3BDYRK1A | |
| SCHEMBL4851322 | 0.77 | LPO (0.47) | ALDH1A1DYRK1A | |
| SCHEMBL4859078 | 0.72 | DYRK1A (0.51) | ALDH1A1NFATC1GSK3BDYRK1A | |
| SCHEMBL4849658 | 0.71 | DYRK1A (0.67) | ALDH1A1NFATC1GSK3BDYRK1A | |
| SCHEMBL4857328 | 0.71 | CYP1B1 (0.42) | NFATC1GSK3BDYRK1A | |
| SCHEMBL4857531 | 0.71 | DYRK1A (0.66) | ALDH1A1NFATC1GSK3BDYRK1A | |
| SCHEMBL29801631 | 0.71 | DYRK1A (0.66) | ALDH1A1NFATC1GSK3BDYRK1A | |
| SCHEMBL4847918 | 0.70 | DYRK1A (0.52) | NFATC1GSK3BDYRK1AMAPK10 | |
| SCHEMBL4849408 | 0.70 | DYRK1A (0.53) | NFATC1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | FNTA 1397/4885FNTB 776/4885PGGT1B 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.